- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.09. | Beeline flies into phase 3 as oral lupus drug soars past placebo | ||
| 09.09. | Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail | ||
| 08.09. | AstraZeneca's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD | ||
| 08.09. | Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins | ||
| 08.09. | Inhibrx CEO says progression-free survival data leave 'no question' about OX40 agonist's durability | ||
| 08.09. | Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending | ||
| 08.09. | Bristol Myers' pivotal CAR-T multiple myeloma trial hits primary endpoint | ||
| 08.09. | Novartis' centerpiece of $12B Avidity buyout flunks 'crucial' phase 3 test | ||
| 07.09. | Novo's blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped | ||
| 04.09. | Menarini signs $771M deal to take Gan & Lee GLP-1 to European market | ||
| 03.09. | Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal | ||
| 03.09. | AbbVie's bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial | ||
| 03.09. | GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset | ||
| 03.09. | Ultragenyx fails phase 3 Angelman test, plots 'significant expense reductions' | ||
| 02.09. | Teva autoimmune antibody notches ph. 2 win in celiac disease | ||
| 02.09. | TScan axes 75% of workforce to make room for solid tumor programs | ||
| 02.09. | SEC, FDA sign info-sharing agreement as a 'signal to the market' on insider trading | ||
| 02.09. | Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen | ||
| 01.09. | Roche inks $1.53B deal for Simcere's B-cell-targeting antibody | ||
| 01.09. | ArsenalBio sheds most of staff in pivot to in vivo CAR-T | ||
| 01.09. | Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor | ||
| 01.09. | GSK catches phase 3 fever after mRNA flu vaccine beats standard shots | ||
| 31.08. | Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push | ||
| 31.08. | ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial | ||
| 31.08. | Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.